InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
-0.13%
)
US TECH 100
19,436.00
(
-0.73%
)
Dow Jones
42,313.00
(
0.33%
)
Brent Oil
72.01
(
0.00%
)
Bitcoin
65,595.92
(
-0.42%
)

Replies to post #80244 on $heff's $tation of $tocks & $olid DD

Replies to #80244 on $heff's $tation of $tocks & $olid DD
icon url

$heff

04/26/14 10:32 AM

#80245 RE: $heff #80244

More upgrades..Jefferies of David Steinberg initiated coverage with hold rating: Supernus $SUPN $9 target; Sagent $SGNT $23 target; Allergan $AGN $139.
icon url

$heff

05/08/14 12:04 AM

#80449 RE: $heff #80244

$PCRX.. submits sNDA for EXPAREL Nerve Block Indication. Expected PDUFA March 5, 2015 http://t.co/wYmF58kyBt
icon url

$heff

05/08/14 3:59 AM

#80455 RE: $heff #80244

$NKTR..ADCOM Update from recent May 7th Earnings Call.."I would like to start with a brief update on Naloxegol. As you know, the FDA advisory committee meeting to discuss OIC drug has now been tentatively scheduled for June 11 and 12 with the anaesthetic and analgesic drug products advisory committee. AstraZeneca and Nektar are actively working together to prepare for the advisory committee meeting and we are looking forward to discussing our robust Phase 3 data set in the context of the other presenting companies."